Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Abruzzese

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Lancet (London, England)|February 22, 2005
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trialM Bocchia, S Gentili, E Abruzzese, et al.
Annals of Hematology|May 10, 2000
A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromesA Venditti, A Tamburini, F Buccisano, et al.
Blood|September 9, 1999
Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantationE Abruzzese, J E Radford, J S Miller, et al.
Annals of Hematology|March 13, 2024
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the "RAMP" Italian multicenter prospective studyF Palandri, G Auteri, E Abruzzese, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 2, 2014
Differences among young adults, adults and elderly chronic myeloid leukemia patientsF Castagnetti, G Gugliotta, M Baccarani, et al.
Leukemia|June 20, 2015
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinibF Castagnetti, G Gugliotta, M Breccia, et al.
Leukemia|June 4, 2010
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapyF J Giles, E Abruzzese, G Rosti, et al.
Frontiers in Pharmacology|April 10, 2023
Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life studyA Iurlo, D Cattaneo, D Consonni, et al.
The New England Journal of Medicine|November 5, 2013
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemiasJ E Cortes, D-W Kim, J Pinilla-Ibarz, et al.
Blood Cancer Journal|September 19, 2015
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatmentD Russo, M Malagola, C Skert, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Lancet (London, England)|February 22, 2005
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trialM Bocchia, S Gentili, E Abruzzese, et al.
Annals of Hematology|May 10, 2000
A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromesA Venditti, A Tamburini, F Buccisano, et al.
Blood|September 9, 1999
Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantationE Abruzzese, J E Radford, J S Miller, et al.
Annals of Hematology|March 13, 2024
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the "RAMP" Italian multicenter prospective studyF Palandri, G Auteri, E Abruzzese, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 2, 2014
Differences among young adults, adults and elderly chronic myeloid leukemia patientsF Castagnetti, G Gugliotta, M Baccarani, et al.
Leukemia|June 20, 2015
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinibF Castagnetti, G Gugliotta, M Breccia, et al.
Leukemia|June 4, 2010
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapyF J Giles, E Abruzzese, G Rosti, et al.
Frontiers in Pharmacology|April 10, 2023
Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life studyA Iurlo, D Cattaneo, D Consonni, et al.
The New England Journal of Medicine|November 5, 2013
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemiasJ E Cortes, D-W Kim, J Pinilla-Ibarz, et al.
Blood Cancer Journal|September 19, 2015
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatmentD Russo, M Malagola, C Skert, et al.
Pageof 3